PacBio Raises Earnings Guidance for Full Year 2023

Published on 08/02/2023 at 17:00

S&P Capital IQ

-1.44%

PacBio raised earnings guidance for full year 2023. For the period, the company expected revenue to be between USD 185 million and USD 190 million, representing 44% to 48% growth over 2022.

Latest news about Pacific Biosciences of California, Inc.

Pacific Biosciences of California, Target ALS Collaborate for Genomic Study	Jun. 02	MT
Pacific Biosciences of California, Inc., Q1 2025 Earnings Call, May 08, 2025	May. 24
Pacbio Expands Distribution in China, Gaining Access to New Clinical Lab Networks Via Haorui Gene	May. 22	CI
PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene	May. 22	RE
Pacific Biosciences of California, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 08	CI
PacBio and Chulalongkorn University Announces Strategic Collaboration to Implement PacBio HiFi Whole Genome Sequencing as Part of Newborn Screening Research Program	May. 05	CI
Pacific Biosciences Says New Technology to Enhance HiFi Sequencing	Apr. 28	MT
Pacific Biosciences of California, Inc. Announces Plans to Improve Methylation Detection in HiFi Chemistry	Apr. 28	CI
Pacific Biosciences of California Selected by Davos Alzheimer's Collaborative as Technology Partner	Apr. 22	MT
Davos Alzheimer's Collaborative Selects PacBio as Technology Partner for Global Project to Advance Alzheimer's Disease Research in North Africa	Apr. 22	CI
Healthcare Stocks Ride a Tariffs-Relief Wave -- Healthcare Roundup	Apr. 09	DJ
Pacific Biosciences of California Sees Lower Q1 Revenue, Plans Job Cuts to Reduce Costs	Apr. 09	MT
Pacbio posts Preliminary Q1 2025 Revenue And Reiterates 2025 Revenue Guidance	Apr. 09	RE
Pacific Biosciences of California, Inc. Reiterates Earnings Guidance for the Full Year 2025	Apr. 09	CI
Pacific Biosciences of California Names Jim Gibson CFO	Mar. 27	MT
Jim Gibson To Join PacBio As Chief Financial Officer	Mar. 27	RE
Pacific Biosciences of California, Inc. Appoints Jim Gibson as Chief Financial Officer, Effective March 31, 2025	Mar. 27	CI
UBS Adjusts Price Target on Pacific Biosciences of California to $1.50 From $2, Keeps Neutral Rating	Feb. 14	MT
Pacific Biosciences of California, Inc., Q4 2024 Earnings Call, Feb 13, 2025	Feb. 13
Pacific Biosciences of California, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	Feb. 13	CI
PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service	Feb. 03	RE
PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service, Effective February 10, 2025	Feb. 03	CI
Pacific Biosciences of California Appoints NeoGenomics CEO to Board of Directors	Jan. 30	MT
PacBio Announces Appointment of Chris Smith to Board of Directors	Jan. 30	CI